title: Optimizing ribavirin dosage: a new challenge to improve treatment efficacy in genotype 1 hepatitis C patients.
authors.affiliation: Service de Médecine Interne et Fédération des Hépatites, CHU Dupuytren, 87042 Limoges cedex, France. veronique.loustaud-ratti@unilim.fr
authors.forename: V
authors.initials: V
authors.lastname: Loustaud-Ratti
authors.forename: F
authors.initials: F
authors.lastname: Stanke-Labesque
authors.forename: P
authors.initials: P
authors.lastname: Marquet
authors.forename: M-C
authors.initials: MC
authors.lastname: Gagnieu
authors.forename: M
authors.initials: M
authors.lastname: Maynard
authors.forename: G
authors.initials: G
authors.lastname: Babany
authors.forename: C
authors.initials: C
authors.lastname: Trépo
mesh_terms: D000740:Anemia / Q000139:chemically induced; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D016903:Drug Monitoring; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000998:Antiviral Agents; D012254:Ribavirin